Abstract:Tau protein misfolding and aggregation are pathological hallmarks of Alzheimer's disease and over twenty neurodegenerative disorders. However, the molecular mechanisms of tau aggregation in vivo remain incompletely understood. There are two types of tau aggregates in the brain: soluble aggregates (oligomers and protofibrils) and insoluble filaments (fibrils). Compared to filamentous aggregates, soluble aggregates are more toxic and exhibit prion-like transmission, providing seeds for templated misfolding. Curiously, in its native state, tau is a highly soluble, heat-stable protein that does not form fibrils by itself, not even when hyperphosphorylated. In vitro studies have found that negatively charged molecules such as heparin, RNA, or arachidonic acid are generally required to induce tau aggregation. Two recent breakthroughs have provided new insights into tau aggregation mechanisms. First, as an intrinsically disordered protein, tau is found to undergo liquid-liquid phase separation (LLPS) both in vitro and inside cells. Second, cryo-electron microscopy has revealed diverse fibrillar tau conformations associated with different neurodegenerative disorders. Nonetheless, only the fibrillar core is structurally resolved, and the remainder of the protein appears as a "fuzzy coat". From this review, it appears that further studies are required (1) to clarify the role of LLPS in tau aggregation; (2) to unveil the structural features of soluble tau aggregates; (3) to understand the involvement of fuzzy coat regions in oligomer and fibril formation.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is about the molecular mechanism of Tau protein aggregation and its role in neurodegenerative diseases. Specifically, the paper explores the following points:
1. **Function and Dysfunction of Tau Protein**:
- The paper first introduces the basic function of Tau protein, that is, its important role as a microtubule - binding protein in regulating microtubule dynamics.
- Then it discusses the abnormal aggregation phenomenon of Tau protein in various neurodegenerative diseases, especially its pathological features in Alzheimer's disease (AD).
2. **Isoforms and Domains of Tau Protein**:
- It describes in detail the different isoforms of Tau protein (such as 0N3R, 1N3R, 2N3R, 0N4R, 1N4R, 2N4R) and their expressions at different developmental stages.
- It explains the four main regions of Tau protein: the N - terminal domain (NTD), the proline - rich domain (PRD), the microtubule - binding domain (MTBD) and the C - terminal domain (CTD), as well as the charge distribution and structural features of these regions.
3. **Inclusions of Tau Protein in Neurodegenerative Diseases**:
- It describes the abnormal aggregation forms of Tau protein in various neurodegenerative diseases, including neurofibrillary tangles (NFTs) in AD and other types of Tau inclusions.
- It classifies different Tauopathies (such as 3R Tauopathy, 4R Tauopathy and mixed 3R/4R Tauopathy), and discusses their pathological features and affected brain regions.
4. **Mechanism of Tau Protein Aggregation**:
- It emphasizes that in the native state, Tau protein is a highly soluble and thermally stable disordered protein and does not spontaneously form fibrils.
- It introduces the factors that induce Tau protein aggregation found in in vitro studies, such as negatively charged molecules (such as heparin, RNA, arachidonic acid, etc.).
- It discusses the latest progress of liquid - liquid phase separation (LLPS) and cryo - electron microscopy (cryo - EM) in understanding the mechanism of Tau protein aggregation.
5. **Structural Diversity of Tau Protein Aggregation**:
- It resolves the core atomic structures of Tau fibrils in different Tauopathies by cryo - EM, revealing the structural differences of Tau fibrils in different diseases.
- It discusses the impact of these structural differences on the pathological mechanism of the disease, and the role of the unresolved "fuzzy coat" region.
6. **Soluble Tau Aggregates**:
- It introduces the discovery of Tau oligomers and protofibrils and their forms of existence in AD tissues.
- It discusses the structure, toxicity of these soluble aggregates and their role in disease transmission.
In general, this paper aims to comprehensively summarize and interpret the molecular mechanism of Tau protein aggregation, especially its role in different neurodegenerative diseases, so as to provide directions and challenges for future research.